Boston Scientific (BSX) Raised to Top Pick at Royal Bank of Canada

The average 1-year price target for (LNC) reveals an average price target of $86.91 per share. Insiders sold a total of 96,585 shares of company stock valued at $2,578,197 over the last ninety days. The shares now trade at $0.24 and have been able to report a change of 28.19% over the past one week. Target Corporation (NYSE:TGT) has declined 16.51% since January 22, 2017 and is downtrending. It has underperformed by 16.31% the S&P500. GSA Capital Partners LLP lifted its holdings in shares of Boston Scientific by 21.9% in the second quarter. The Price to Sales (P/S) of the stock is 4.3, while P/B (Price to Book) stands at 5.

The Walt Disney Company (DIS) shares Jumped 0.15% and ended the day at $110.59. Boston Scientific Corporation (BSX) average trading volume of 9,007,080 during the past month is 31.26% above its average volume over the past year, indicating that investors have been more active than usual in the stock in recent times. As higher figure of institutional mostly indicates intentions of capital gain, which is suitable for passive investors as well stocks with a large amount of institutional ownership are often looked upon favorably. 3,659 Comcast Corporation (NASDAQ:CMCSA) shares with value of $144,915 were sold by Murdock Daniel C. Another trade for 583,835 shares valued at $22.57M was made by ROBERTS BRIAN L on Thursday, December 14.

Boston Scientific Corporation (BSX) performance during the last one year upgraded 15.79 percent, while its year to date (YTD) performance showed a positive trend of 11.54 percent. It has outperformed by 2.42% the S&P500. The firm attains analyst recommendation of 1.70 on scale of 1-5 with week's performance of 0.91%. BMO Capital Markets reissued a "buy" rating and set a $30.00 target price on shares of Boston Scientific in a research note on Friday, October 13th. The rating was maintained by Raymond James on Friday, February 10 with "Outperform". As per Tuesday, January 9, the company rating was maintained by Stifel Nicolaus. Jefferies maintained the shares of BSX in report on Tuesday, June 27 with "Hold" rating. Barclays Capital maintained the shares of H in report on Friday, June 17 with " rating. The company was downgraded on Monday, January 25 by National Bank Canada. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider's stock valued at $138,928,000 after purchasing an additional 2,850,630 shares during the period.

Investors sentiment increased to 1.4 in 2017 Q3. The short ratio for BSX is 1.11 while that of AKER is just 0.04. Blackrock invested in 10,129 shares. 1 funds opened positions while 2 raised stakes. Tiger Management Limited Liability holds 1.07M shares or 5.64% of its portfolio. That's a potential 10.86 increase relative to where Boston Scientific Corporation (NYSE:BSX) has been trading recently. Highlander Cap Mngmt Llc owns 0.33% invested in CNX Resources Corporation (NYSE:CNX) for 24,650 shares. Advisor Partners Ltd Com holds 26,937 shares or 0.15% of its portfolio. 78,115 were accumulated by United Asset Strategies Inc.

Boston Scientific Corporation (NYSE:BSX) shares were trading higher by 0.22 percent ($0.06) at $27.71 a piece in Monday's session. The medical equipment provider reported $0.31 earnings per share for the quarter, meeting the consensus estimate of $0.31. BSX's institutional ownership stands at 94.40%. Rhumbline Advisers reported 2.37M shares stake. 289 are held by Assetmark. The debt ratio of BSX is 0.75 compared to 0.00 for AKER. After having $-0.15 EPS previously, CNX Resources Corporation's analysts see -260.00% EPS growth. Boston Scientific Corporation has a 1-year low of $23.29 and a 1-year high of $29.93. Therefore 38% are positive. Boston Scientific Corporation had 85 analyst reports since July 27, 2015 according to SRatingsIntel. The stock has "Buy" rating by Buckingham Research on Monday, January 8. This implies that they believe the stock has what it takes to lift the price another 8.95%. As per Thursday, July 23, the company rating was maintained by Benchmark. Morgan Stanley has "Equal-Weight" rating and $29 target.

The collective rating of 1.7 for Boston Scientific Corporation (NYSE:BSX) also leans strongly towards the bullish end of the spectrum. Finally, Zacks Investment Research lowered Boston Scientific from a "hold" rating to a "sell" rating in a research report on Monday, October 16th. Needham has "Buy" rating and $28 target. (NYSE:CHD) has risen 0.39% since January 23, 2017 and is uptrending. Needham has "Buy" rating and $32.0 target. The rating was maintained by SunTrust with "Buy" on Tuesday, October 31.

Since August 1, 2017, it had 0 buys, and 13 insider sales for $15.16 million activity. The insider Carruthers Wendy sold $332,584. Nanavaty Maulik had sold 57,031 shares worth $1.56 million. 7,900 shares were sold by Sorenson John Bradley, worth $208,328 on Wednesday, August 2.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Latest news

Physician who fled Poland faces deportation from the US
She recalls their mother becoming a naturalized citizen but, is unsure if she obtained citizenship before Lucasz's 18th birthday. ICE also said Niec recently came under scrutiny because of 18 so-called "encounters" with local law enforcement.

Malayalam film actor-director Sreenivasan hospitalised
Meanwhile, his son Vineeth took to Facebook to tell the fans about the condition of his father. Sreenivasan is also an acclaimed screenwriter, filmmaker, and producer of Malayalam cinema.

Jimmy Kimmel Traumatized From Last Year's Best Picture Mix-Up in Oscars Promo
Jimmy proceeds to have flashbacks to the moment before saying, "And the worst part is they want me to do it again". The camera pans out to reveal a patiently listening Warren Beatty reluctantly playing the part of therapist.

Mi 6X to be powered by Xiaomi's Surge S2 octa-core processor
The image also suggests the presence of a thin top bezel and none at the bottom, reminding us of the Mi MIX 2 design. However, unlike the recent leaks we have seen, this one sheds light at the rear panel of the smartphone.

Dissecting the Insider Trading Patterns of Celgene Corporation (CELG)
The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Zacks' consensus estimate of $1.61 by $0.21. The investor is now holding $31.53 million shares due in part to a decrease of 876768 new shares in their portfolio.

Other news